Antibody CDR3-VH Repertoire Data from Phage Display Against PS-Modified Oligonucleotides

Deep sequencing of phage display selections identified a shared set of 113 CDR3-VH clonotypes with a convergent physicochemical signature for binding phosphorothioate-modified antisense oligonucleotides. The data, generated via Illumina MiSeq sequencing and a dedicated bioinformatic pipeline, includes clonotype counts, CPM normalization, and physicochemical descriptor profiling. Representative functional assays, such as ELISA and fluorescence microscopy, validate the biological relevance of the identified antibody signatures.

Use Cases

• Identifying convergent antibody sequence motifs based on clonotype enrichment analysis.
• Profiling physicochemical properties of CDR3 regions for rational antibody design against polyanionic targets.
• Benchmarking bioinformatic pipelines for processing next-generation sequencing data from phage display experiments.
• Correlating in vitro binding assay results (e.g., ELISA) with deep sequencing-derived clonal frequencies.

Strengths

• Data is derived from two independent phage display biopanning strategies, supporting reproducibility.
• Analysis includes a defined set of 113 shared CDR3-VH clonotypes, providing a specific signature for study.
• Dataset is openly available under a CC-BY-4.0 license, facilitating reuse.

Limitations

• Column names and exact row counts are not specified in the provided metadata, limiting immediate understanding of data structure.
• The dataset appears to be split across multiple file entries (PDF and XLSX) with differing reported file sizes (34,849 and 165,089), suggesting potential inconsistency in what is shared.
• Temporal coverage of the underlying experiments is not provided.

Provenance

Source

Riccardo Galasso

Collection Method

Generated via next-generation sequencing (Illumina MiSeq) of phage display libraries after biopanning against biotinylated phosphorothioate-modified antisense oligonucleotides.

Freshness

Last updated 2026-05-29.